Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema

Mark Hassall, Nicholas Andrew

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Taxanes are a class of microtubule stabilising agents used to treat a wide range of malignancies. Taxane drug-induced cystoid macula oedema (TDICMO) is a known but rare complication of therapy. First reported with Docetaxel in 2003 and Paclitaxel in 2007, there are currently less than 20 cases of TDICMO in the literature. Although most cases resolve following taxane cessation, several authors have tried using carbonic anhydrase inhibitors or intravitreal bevacizumab to accelerate resolution or when taxane therapy cannot be discontinued. We report the first published case of TDICMO treated with a single-eye trial of topical dorzolamide versus intravitreal bevacizumab.

    Original languageEnglish
    Article number599
    Number of pages4
    JournalBMJ Case Reports
    Volume2016
    DOIs
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema'. Together they form a unique fingerprint.

  • Cite this